| |
|
|
| |
|
|
| |
HUM-MOLGEN
-> Events
-> Meetings and Conferences |
|
|
| |
| |
| |
December 21, 2022 |
|
|
| |
|
|
| |
|
|
|
Xtalks, online
2023 -2-01
The value of real-world data is clear. The acceptance of real-world evidence (RWE) is growing. But is this enough to propel RWE from being a nice-to-have to a must-have?
PicnicHealth is hosting a four-part webinar series to reframe the “ROI” for RWE generation and tackle the question: beyond the return on investment for RWE, what is the risk of inaction?
This webinar will explore relevant examples of how Data Science and Digital Health are accelerating pharmaceutical innovation and driving impact for patients. Bringing together global experts with diverse perspectives spanning regulatory, R&D and health tech, this conversation will highlight innovative, RWD-driven approaches to drug development and regulatory decision-making. Speakers will discuss the need for different types of data to construct a complete clinical picture – and how a data-driven approach can drive impact across both research and clinical practice.
Register today to learn more about the transformational value of real-world data for drug development and regulatory decision-making.
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Jesper Kjær, Director of The Data Analytics Centre at the Danish Medicines Agency, Co-Chair for HMA / EMA Big Data Steering Group Najat Khan, Chief Data Science Officer and Global Head of Strategy & Operations, Janssen Research & Development Noga Leviner, Co-Founder & CEO, PicnicHealth (Moderator) Evelyn Pyper, Evidence Strategist, PicnicHealth
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2023 -2-01
|
|
|
|
|
|
|
|
Registration:
|
|
Free registration
|
|
|
E-mail:
|
|
ajuurinen@xtalks.com
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp,
Frank S.
Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved.
Liability, Copyright and Imprint. |
|